Summit Therapeutics, an antibiotic innovation international firm, has announced that it has raised approximately £38m, which was approved by shareholders at the Company’s general meeting held on 23 December 2019.
Completion of the fundraising meant that the proposed restructuring of the Company’s board of directors is now effective.
The restructured Board now comprises Robert W. Duggan, Manmeet Soni, Dr Elaine Stracker and Dr Ventzislav Stefanov as non-executive directors, and Glyn Edwards as Chairman in addition to his role as the company’s Chief Executive Officer. Dr Frank Armstrong, Leopoldo Zambeletti and David Wurzer stepped down from the board.
The person responsible for arranging for the release of this announcement on behalf of the Company is Richard Pye, Vice President, Investor Relations and Corporate Affairs.